FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296007231> ?p ?o ?g. }

• W4296007231 endingPage "S732" @default.
• W4296007231 startingPage "S731" @default.
• W4296007231 abstract "Currently high risk locally advanced rectal cancer (LARC) patients (pts) are treated with intensified neoadjuvant chemotherapy and radiation (TNT). The previous study SAKK 41/08 showed that adding Sorafenib to long course chemoradiation (LcCRT) is highly active. This potential improvement in clinical outcome by adding a multi-TKI as Regorafenib (R) to LcCRT was investigated in the SAKK 41/16 trial. Pts with T3-4 and/or N+ M0 rectal cancer were included. Neoadjuvant LcRCT was given with Capecitabine 825mg/m2d1-d38 and 28 fractions of 1.8Gy (50.4Gy). R was added d1-14 and d22-35. The phase I part was done in a 3+3 dose escalation (DE) scheme for R. The recommended dose (RD) was used for the cohort expansion (CE). The primary endpoints included dose limiting toxicity (DLT) and pathological response (defined as near complete regression [npCR] or complete regression [pCR] according to Dworak) for the CE. 19 pts were required based on a one-sided type I error 20% and a power 80% for assuming a npCR/pCR rate of ≥ 40% for H1 compared to npCR/pCR rate of ≤ 20% for H0.. 25 pts were included. Two DLT occurred with R 120mg, ending in a RD of 80mg daily. 19 pts were treated with the RD, 8 pts (42.1%; one-sided 80% CI (lower bound): 30.7%; 95% CI: 20.3%-66.5%) reached the primary endpoint (5 pts [26.3%] had npCR and 3 pts [15.8%] had pCR). One additional patient received no surgery due to clinical CR. Downstaging of T and/or N was seen in 15 of 18 operated pts (83.3%). All pts had R0 resection and clear circumferential margin. Postoperative complications occurred in 6 pts (35.3%), one anastomotic leak grade G4, 3 pts with local infections. The most common treatment related adverse events ≥ G3 in the CE were diarrhea and rectal anastomotic leak in 2 pts each. Adding Regorafenib in RD 80 mg to LcCRT in LARC reached both primary endpoints and showed high activity. This regimen did not prolong the neoadjuvant treatment time in contrast to TNT. Toxicity was manageable, and postoperative complications were as expected. This regimen deserves further investigation especially in efficacy comparision to TNT regimens." @default.
• W4296007231 created "2022-09-17" @default.
• W4296007231 creator A5008642365 @default.
• W4296007231 creator A5012174779 @default.
• W4296007231 creator A5021074482 @default.
• W4296007231 creator A5022167252 @default.
• W4296007231 creator A5023510680 @default.
• W4296007231 creator A5035736007 @default.
• W4296007231 creator A5039341309 @default.
• W4296007231 creator A5047846380 @default.
• W4296007231 creator A5057098162 @default.
• W4296007231 creator A5066402682 @default.
• W4296007231 creator A5071805546 @default.
• W4296007231 creator A5076662858 @default.
• W4296007231 creator A5080158628 @default.
• W4296007231 creator A5086720156 @default.
• W4296007231 creator A5087142746 @default.
• W4296007231 creator A5091503079 @default.
• W4296007231 date "2022-09-01" @default.
• W4296007231 modified "2023-09-27" @default.
• W4296007231 title "431P Neoadjuvant treatment with regorafenib and capecitabine combined with radiotherapy in locally advanced rectal cancer: A multicenter phase Ib trial (RECAP) SAKK 41/16" @default.
• W4296007231 doi "https://doi.org/10.1016/j.annonc.2022.07.569" @default.
• W4296007231 hasPublicationYear "2022" @default.
• W4296007231 type Work @default.
• W4296007231 citedByCount "0" @default.
• W4296007231 crossrefType "journal-article" @default.
• W4296007231 hasAuthorship W4296007231A5008642365 @default.
• W4296007231 hasAuthorship W4296007231A5012174779 @default.
• W4296007231 hasAuthorship W4296007231A5021074482 @default.
• W4296007231 hasAuthorship W4296007231A5022167252 @default.
• W4296007231 hasAuthorship W4296007231A5023510680 @default.
• W4296007231 hasAuthorship W4296007231A5035736007 @default.
• W4296007231 hasAuthorship W4296007231A5039341309 @default.
• W4296007231 hasAuthorship W4296007231A5047846380 @default.
• W4296007231 hasAuthorship W4296007231A5057098162 @default.
• W4296007231 hasAuthorship W4296007231A5066402682 @default.
• W4296007231 hasAuthorship W4296007231A5071805546 @default.
• W4296007231 hasAuthorship W4296007231A5076662858 @default.
• W4296007231 hasAuthorship W4296007231A5080158628 @default.
• W4296007231 hasAuthorship W4296007231A5086720156 @default.
• W4296007231 hasAuthorship W4296007231A5087142746 @default.
• W4296007231 hasAuthorship W4296007231A5091503079 @default.
• W4296007231 hasBestOaLocation W42960072311 @default.
• W4296007231 hasConcept C121608353 @default.
• W4296007231 hasConcept C126322002 @default.
• W4296007231 hasConcept C141071460 @default.
• W4296007231 hasConcept C143998085 @default.
• W4296007231 hasConcept C203092338 @default.
• W4296007231 hasConcept C2776248978 @default.
• W4296007231 hasConcept C2776694085 @default.
• W4296007231 hasConcept C2777909004 @default.
• W4296007231 hasConcept C2778292576 @default.
• W4296007231 hasConcept C31760486 @default.
• W4296007231 hasConcept C526805850 @default.
• W4296007231 hasConcept C530470458 @default.
• W4296007231 hasConcept C535046627 @default.
• W4296007231 hasConcept C71924100 @default.
• W4296007231 hasConcept C90924648 @default.
• W4296007231 hasConceptScore W4296007231C121608353 @default.
• W4296007231 hasConceptScore W4296007231C126322002 @default.
• W4296007231 hasConceptScore W4296007231C141071460 @default.
• W4296007231 hasConceptScore W4296007231C143998085 @default.
• W4296007231 hasConceptScore W4296007231C203092338 @default.
• W4296007231 hasConceptScore W4296007231C2776248978 @default.
• W4296007231 hasConceptScore W4296007231C2776694085 @default.
• W4296007231 hasConceptScore W4296007231C2777909004 @default.
• W4296007231 hasConceptScore W4296007231C2778292576 @default.
• W4296007231 hasConceptScore W4296007231C31760486 @default.
• W4296007231 hasConceptScore W4296007231C526805850 @default.
• W4296007231 hasConceptScore W4296007231C530470458 @default.
• W4296007231 hasConceptScore W4296007231C535046627 @default.
• W4296007231 hasConceptScore W4296007231C71924100 @default.
• W4296007231 hasConceptScore W4296007231C90924648 @default.
• W4296007231 hasLocation W42960072311 @default.
• W4296007231 hasOpenAccess W4296007231 @default.
• W4296007231 hasPrimaryLocation W42960072311 @default.
• W4296007231 hasRelatedWork W2002928668 @default.
• W4296007231 hasRelatedWork W2029040122 @default.
• W4296007231 hasRelatedWork W2139955290 @default.
• W4296007231 hasRelatedWork W2145753255 @default.
• W4296007231 hasRelatedWork W2465617904 @default.
• W4296007231 hasRelatedWork W2601851885 @default.
• W4296007231 hasRelatedWork W349909140 @default.
• W4296007231 hasRelatedWork W4281683249 @default.
• W4296007231 hasRelatedWork W4308886650 @default.
• W4296007231 hasRelatedWork W4317891425 @default.
• W4296007231 hasVolume "33" @default.
• W4296007231 isParatext "false" @default.
• W4296007231 isRetracted "false" @default.
• W4296007231 workType "article" @default.